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Abstract. S100 calcium-binding protein B (S100B) is highly 
expressed in glioma cells and promotes cancer cell survival 
via inhibition of the p53 protein. In melanoma cells, this 
S100B-p53 interaction is known to be inhibited by pentami-
dine isethionate, an antiprotozoal agent. Thus, the aim of the 
present study was to evaluate the effect of pentamidine on rat 
C6 glioma cell proliferation, migration and apoptosis in vitro. 
The change in C6 cell proliferation following treatment with 
pentamidine was determined by performing a 3-[4,5-dimethyl-
thiazol-2-yl]-2,5 diphenyltetrazolium bromide-formazan assay. 
Significant dose‑dependent decreases in proliferation were 
observed at pentamidine concentrations of 0.05 µM (58.5±5%; 
P<0.05), 0.5 µM (40.6±7%; P<0.01) and 5 µM (13±4%; P<0.001) 
compared with the control (100% viability). Furthermore, 
treatment with 0.05, 0.5 and 5 µM pentamidine was associated 
with a significant increase in apoptosis versus the untreated 
cells, as determined by DNA fragmentation assays, immuno-
fluorescence analysis of C6 chromatin using Hoechst staining, 
and immunoblot analysis of B-cell lymphoma-2 (Bcl-2)-asso-
ciated X protein (100%, P<0.05; 453%, P<0.01; and 1000%, 
P<0.001, respectively) and Bcl-2 (-60%, P<0.001; -80.13%, 
P<0.001; -95%, P<0.001, respectively). In addition, the 
administration of 0.05, 0.5 and 5 µM pentamidine significantly 
upregulated the protein expression levels of p53 (681±87.5%, 
P<0.05; 1244±94.3%, P<0.01; and 2244±111%, P<0.001, respec-
tively), and significantly downregulated the expression levels 
of matrix metalloproteinase-2 (42±2.3%, P<0.05; 71±2.5%, 
P<0.01; and 95.8±3.3%, P<0.001, respectively) and aqua-
porin 4 (38±2.5%, P<0.05; 69±2.6%, P<0.01; and 88±3.0%, 
P<0.001, respectively), compared with the untreated cells. 
The wound healing assay demonstrated that cell migration 
was significantly impaired by treatment with 0.05, 0.5 and 
5 µM pentamidine compared with untreated cells (88±4.2%, 
P<0.05; 64±2%, P<0.01; and 42±3.1%, P<0.001, respectively). 
Although additional in vivo studies are required to clarify the 
current in vitro data, the present study indicates that pentami-
dine and S100B-p53 inhibitors may represent a novel approach 
for the treatment of glioma.
Introduction
Glioma is one of the most prevalent and aggressive malig-
nant primary tumors of the central nervous system (CNS), 
accounting for 52 and 20% of all cases of brain tissue and 
intracranial tumors, respectively (1,2). It is associated with 
a poor prognosis, particularly in high grade tumors, such as 
glioblastoma multiforme (3). The median life expectancy of 
patients with malignant glioma is ~12 months, with a 5-year 
survival rate after diagnosis of <5% (4,5). Although systemic 
metastases are relatively rare, the infiltrative nature of glioma 
cells, which are able to migrate into the surrounding brain 
parenchyma, means achieving total surgical resection is 
unlikely (6,7). Considering that complete curative resection 
and radiotherapy are not yet attainable, adjuvant chemotherapy 
is of major importance in the treatment of malignant gliomas, 
providing the rationale for the implementation of novel 
targeted therapies. Thus, the development of novel therapeutic 
approaches to effectively treat gliomas and increase the posi-
tive outcome rate is currently a significant topic in the field of 
oncology.
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S100 calcium-binding protein B (S100B) is a 20 kDa, 
diffusible, Ca+2/Zn+2-p53 binding protein that has emerged as 
a critical signaling molecule as it regulates numerous phys-
iopathological functions including, inflammation, apoptosis 
and cell growth (8). S100B appears to be upregulated in 
numerous neurodegenerative diseases, including Alzheimer's 
and Parkinson's disease, and is known to be overexpressed in 
the majority of malignant gliomas (9-11). Furthermore, the 
S100B protein has been proposed to significantly contribute 
to cancer development by inhibiting the function of tumor 
suppressor protein p53 (12,13), and by stimulating the activity 
of the mitogenic kinases nuclear dbf2-related (14) and protein 
kinase B (15). Evidence of S100B/p53 crosstalk, and its 
impact on cell proliferation and survival, has been the focus of 
research efforts regarding the development of inhibitors of the 
S100B-p53 protein-protein interaction. This molecular para-
digm represents a novel target for the treatment of the majority 
of aggressive types of cancer in which S100B protein is highly 
expressed, such as melanoma (16). For analogous reasons, 
direct molecular targeting of the S100B protein in glioma 
appears to be an innovative approach for the development of 
novel therapeutic interventions against this form of cancer.
Pentamidine isethionate, an agent that exhibits 
antiprotozoal activity and is approved for the treatment of Pneu‑
mocystis cariini pneumonia in the United States, appears to be 
a promising candidate for the aforementioned S100B-targeting 
of glioma. In addition to its antiprotozoal activity, pentami-
dine has been reported to inhibit the S100B-p53 interaction 
in vitro in melanoma cells (17). However, to the best of our 
knowledge, no data has yet been determined regarding the 
possible antiproliferative and antimigratory effects exerted by 
pentamidine on glioma cells. Therefore, the present study used 
C6 rat glioma cell cultures to evaluate the in vitro effects of 
pentamidine on cell proliferation and survival. C6 cells were 
utilized as a number of studies have revealed that the changes 
in gene expression observed in the C6 cell line closely resem-
bles those reported in human brain tumors (18-21). Notably, 
C6 rat glioma cells possess the most important features of 
human gliomas, exhibiting a mutant p16/cyclin-dependent 
kinase inhibitor 2a/Ink4a locus (22), high S100B expression 
levels and no expression of the p53 protein (23). Thus, C6 rat 
glioma cells are ideal candidates for exploring the activity of 
novel compounds with anti-glioma activity.
Materials and methods
Materials. Media, substances and reagents for cell cultures 
were all purchased from Sigma-Aldrich (St. Louis, MO, 
USA), unless otherwise stated. Instruments, reagents and 
materials for western blot analysis were obtained from 
Bio-Rad Laboratories (Milan, Italy), and pentamidine isethi-
onate was purchased from Tocris Cookson, Inc. (Ballwin, 
MO, USA). Monoclonal mouse anti-p53 (cat. no. sc-393031, 
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), 
polyclonal rabbit anti-matrix metalloproteinase-2 (MMP-2; 
cat. no. ab37150, Abcam, Cambridge, UK), polyclonal mouse 
anti-β-actin (cat. no. sc-130656, Santa Cruz Biotechnology 
Inc.); polyclonal mouse anti-B-cell lymphoma-2 (Bcl-2)-as-
sociated X protein (BAX; cat. no. ab18210), monoclonal 
rabbit anti-Bcl-2 (cat. no. ab87435) and monoclonal rabbit 
anti-aquaporin 4 (AQP4; cat. no. ab128906) antibodies were 
obtained from Abcam (Cambridge, UK); and polyclonal rabbit 
anti-mouse IgG from Dako (Glostrup, Denmark).
Cell culture and pentamidine treatment. C6 rat glioma 
cells (American Type Culture Collection, LGC Standards, 
Middlesex, UK) were cultured in Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 5% fetal bovine serum 
(FBS), 2 mM glutamine, 100 U/ml penicillin, and 100 µg/ml 
streptomycin in a humidified atmosphere of 5% CO2 and 95% 
air at a temperature of 37˚C. A total of 1x106 cells/well were 
plated and incubated for 24 h under the same conditions as 
those utilised for the initial culture. Upon reaching confluence, 
the cells were washed three times with phosphate-buffered 
saline (PBS), detached with trypsin/EDTA, plated in 10-cm 
diameter petri dish and allowed to adhere for 24 h. Subse-
quently, DMEM was replaced with fresh medium, and the cells 
were treated with increasing concentrations of pentamidine 
isethionate (0.05, 0.5 and 5 µM) dissolved in ultrapure and 
pyrogen-free sterile water at different time points, as described 
below. The pentamidine concentrations used in the current 
experiments were selected according to the results of a series 
of pilot experiments aimed at identifying the lowest effective 
concentration (data not shown).
Cel l  p ro l i f e ra t io n  a n d  su r v iva l  a s s a ys.  Cel l 
proliferation was evaluated by performing a 3-[4,5-dimeth-
ylthiazol-2-yl]-2,5 diphenyltetrazolium bromide (MTT) 
assay (24). In brief, C6 cells (5x104) were plated in 96-well 
plates and allowed to adhere for 2 h. After 2 h, DMEM was 
replaced with fresh medium and the cells were treated with 
increasing concentrations pentamidine (0.05, 0.5 and 5 µM). 
After 48 h, 25 µl MTT (5 mg/ml MTT in DMEM) was added 
to the cells and the mixture was incubated for an additional 3 h 
at 37˚C. Subsequently, the cells were lysed and the dark blue 
crystals were solubilized using a 125-µl solution containing 
50% N,N-dimethylformamide and 20% (w/v) sodium 
dodecylsulphate (pH 4.5). The optical density (OD) of each 
well was determined using a PerkinElmer, Inc. (Waltham, 
MA, USA) microplate spectrophotometer equipped with 
a 620-nm filter. Cell viability in response to pentamidine 
administration was calculated using the following equation: 
Cell viability (%) = (ODtreated / ODcontrol) x 100.
Apoptotic cell staining. A total of 5x105 cells were seeded onto 
glass slides, treated with pentamidine (0.5-5 µM) for 2 h, washed 
twice with PBS and fixed with paraformaldehyde for 30 min at 
4˚C. The C6 cells were stained with Hoechst 33258 for 5 min 
prior to analysis by fluorescent microscopy analysis using 
a Nikon Eclipse 80 microscope (Nikon Instruments, Inc., 
Amsterdam, Netherlands), and images were captured 
at a magnification of x10 using a high-resolution digital 
camera (Nikon Digital Sight DS-U1; Nikon Instruments, Inc.). 
Apoptotic cells were characterized by the specific morpho-
logical alterations of condensed nuclei and cell shrinkage and 
counted using CellProfiler 2.1.0 software (Broad Institute, 
Cambridge, MA, USA).
DNA fragmentation assay. Following treatment with pentami-
dine, the adherent and non-adherent C6 cells were harvested, 
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lysed with 400 µl sodium chloride EDTA buffer (75 mM NaCl 
and 25 mM EDTA) containing 1% (w/v) SDS and 2 U/ml 
proteinase K, and incubated for 2 h at 55˚C. Proteins were 
precipitated by adding 140 µl 5 M NaCl. After centrifugation 
at 11,000 x g for 15 min, DNA in the supernatant was precipi-
tated by addition of 1x103 ml ethanol and centrifugation 
was performed again (15 min; 11,000 x g). After washing 
with 70% ethanol (v/v), the DNA was resuspended in H2O, 
separated by agarose gel electrophoresis and stained with 
ethidium bromide.
Western blot analysis. Protein expression in the C6 cells was 
evaluated by performing a western blot analysis. Following 
treatment with pentamidine, cells (1x106) were harvested, 
washed twice with ice-cold PBS and centrifuged at 180 x g 
for 10 min at 4˚C. The cell pellet was resuspended in 100 µl 
ice-cold hypotonic lysis buffer (10 mM HEPES, 1.5 mM 
MgCl2, 10 mM KCl, 0.5 mM phenylmethylsulphonylfluoride, 
1.5 µg/ml soybean trypsin inhibitor, 7 µg/ml pepstatin A, 
5 µg/ml leupeptin, 0.1 mM benzamidine and 0.5 mM DTT). 
To lyse the cells, the suspension was rapidly passed through 
a syringe needle five to six times prior to centrifugation for 
15 min at 13,000 x g to obtain the cytoplasmic fraction. The 
cytosolic fraction proteins were mixed with non-reducing gel 
loading buffer (50 mM Tris, 10% SDS, 10% glycerol, 2 mg 
bromophenol/ml) at a 1:1 ratio, boiled for 3 min and centri-
fuged at 10,000 x g for 10 min. The protein concentration 
was determined using a Bradford assay and equivalent quan-
tities (100 µg) of each sample were electrophoresed on a 12% 
discontinuous polyacrylamide minigel (25). Subsequently, 
the proteins were transferred onto nitrocellulose membranes 
that had been saturated by incubation with 10% non-fat 
dry milk in 1X PBS overnight at 4˚C. Each membrane was 
incubated with mouse anti-BAX (dilution, 1:1000), mouse 
anti-Bcl-2 (dilution, 1:2000), rabbit anti-MMP-2 (dilu-
tion, 1:1000), mouse anti-AQP4 (dilution, 1:5000), mouse 
anti-p53, (dilution, 1:1000) or mouse anti-β-actin (dilu-
tion, 1:1,000) antibodies for 2 h at room temperature (RT). 
Figure 1. Pentamidine exerts a pro-apoptotic effect on cultured C6 rat glioma cells. (A) An MTT absorbance assay was conducted to determine that pentami-
dine (0.05, 0.5 and 5 µM) induces concentration‑dependent inhibition of C6 rat glioma cell proliferation after 48 h. (B) Hoechst staining of C6 rat glioma cell 
nuclei in the presence or absence of pentamidine (0.05, 0.5 and 5 µM) and the relative proportion (%) of apoptotic nuclei. Pentamidine induces a concentra-
tion-dependent increase in the nuclear density of chromatin (arrows) as a marker of apoptosis (scale bar, 20 µm). (C) Agarose gel electrophoresis of cultured C6 
rat glioma cell DNA in the presence or absence of pentamidine (0.05, 0.5 and 5 µM) for 48 h. The results are representative of n=3 independent experiments. 
(D) Western blot analysis of pro-apoptotic BAX and anti-apoptotic Bcl-2 proteins. Pentamidine (0.05, 0.5 and 5 µM) induces a concentration-dependent 
increase in BAX expression and a parallel decrease in Bcl-2 expression, demonstrating a clear pro-apoptotic balance in the C6 rat glioma cells. (E) Relative 
quantification of immunoreactive bands of Bcl‑2 and BAX proteins (arbitrary units). Results are expressed as the mean ± standard error of the mean of n=5 
experiments performed in triplicate. *P<0.05; **P<0.01; and ***P<0.001 vs. ctrl cells. MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide; 
ctrl, control; BAX, B-cell lymphoma-2-associated X protein; Bcl-2, B-cell lymphoma-2.
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The membranes were then incubated with polyclonal rabbit 
anti-mouse or goat anti-rabbit IgG coupled to horseradish 
peroxidase (dilution, 1:2000; cat. nos. P0260 and P0448, 
respectively; Dako, Glostrup, Denmark). Immune complexes 
were revealed using enhanced chemiluminescence detection 
reagents (GE Healthcare Life Sciences, Milan, Italy) and by 
exposing the membranes to Kodak X‑Omat film (Eastman 
Kodak Co., Rochester, NY, USA). Protein bands were then 
scanned and underwent densitometric analysis using a 
GS-700 imaging densitometer (Bio-Rad Laboratories).
Wound healing assay. A wound healing assay using the C6 cells 
was performed as described previously, with a number of 
modifications (26). Briefly, the C6 cells (5x105 cells/well) were 
plated on a six-well plate and incubated for 24 h in DMEM 
supplemented with 5% fetal bovine serum (FBS), 2 mM gluta-
mine, 100 U/ml penicillin, and 100 µg/ml streptomycin in a 
humidified atmosphere of 5% CO2 and 95% air at a tempera-
ture of 37˚C. The cell layer was scratched using a 200‑µl sterile 
pipette tip, then cells were washed with PBS three times and 
incubated with 0.05, 0.5 and 5 µM pentamidine for 48 h. The 
cells were washed twice with PBS and fixed with 4% parafor-
maldehyde for 30 min. In order to facilitate cell counting, the 
nucleus of the C6 cells was stained with Hoechst 33258 (Invit-
rogen Life Technologies, Carlsbad, CA, USA) for 5 min at RT. 
The cells were subsequently washed three times with PBS and 
images were captured using a Nikon Eclipse 80 microscope 
equipped with a high-resolution digital camera (Nikon Digital 
Sight DS-U1; Nikon Instruments, Inc.). The percentage of 
migration was calculated by counting the number of cells that 
had migrated into scratched areas compared with the number 
of cells that had remained in the peripheral areas.
Statistical analysis. Results are expressed as the mean ± stan-
dard error of the mean of n experiments. Statistical analyses 
were performed using one-way analysis of variance and 
multiple comparisons were performed using a Bonferroni 
post hoc test. P<0.05 was considered to indicate a statisti-
cally significant difference.
Results
Effect of pentamidine on C6 cell proliferation and apoptosis. 
The administration of pentamidine (0.05, 0.5 and 5 µM) 
to C6 cells caused a significant concentration-dependent 
decrease in cell viability (58.5±5%, P<0.05; 40.6±7%, 
P<0.01; and 13±4%, P<0.001, respectively) compared with 
the unstimulated cells (assumed 100% viability; Fig. 1A). In 
agreement with this data, a Hoechst assay demonstrated that 
treatment with pentamidine resulted in a pro-apoptotic effect, 
with the apoptotic process detected in cell nuclei 48 h after 
treatment (Fig. 1B). Furthermore, the pentamidine concentra-
tion (0.05, 0.5 and 5 µM) was significantly associated with 
an increase in the proportion of apoptotic nuclei (21±5%, 
P<0.05; 39±3.2%, P<0.01; and 88±4.1%, P<0.001, respectively) 
compared with the untreated C6 cells (4.5±1.6%). In addition, 
the integrity of the DNA samples extracted from the C6 cells 
after treatment with pentamidine for 48 h was analyzed using 
agarose gel electrophoresis and compared with the DNA 
samples obtained from the untreated C6 cells. Qualitative 
analysis of the DNA demonstrated that pentamidine treat-
ment (0.05, 0.5 and 5 µM) increased the amount of smearing 
on the gel in a concentration-dependent manner, while DNA 
obtained from the untreated cells only travelled a short distance 
through the gel, indicating its integrity (Fig. 1C). Immunoblot 
Figure 2. Effect of pentamidine on p53, MMP-2 and AQP4 protein expression levels in C6 rat glioma cells. (A) Western blot analysis demonstrated the effect 
of pentamidine on p53, MMP‑2 and AQP4 protein expression levels in C6 rat glioma cells. (B) Relative quantification of the immunoreactive bands of p53, 
MMP-2 and AQP4 protein (arbitrary units). Results are expressed as the mean ± standard error of the mean of n=5 experiments performed in triplicate. *P<0.05; 
**P<0.01; and ***P<0.001 vs. ctrl cells. Ctrl. control; MMP-2, matrix metalloprotein-2; AQP4, aquaporin 4; OD, optical density.
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analysis of BAX and Bcl-2 determined that pentamidine treat-
ment (0.05, 0.5 and 5 µM) induced a significant upregulation 
in BAX protein expression levels in a concentration-dependent 
manner (100%, P<0.05; 453%, P<0.01; and 1000%, P<0.001, 
respectively) compared with the untreated cells (Fig. 1D and E). 
This significant increase in the pro‑apoptotic effector BAX 
was paralleled to a significant and concentration‑dependent 
decrease in Bcl-2 protein expression levels following the treat-
ment of C6 cells with 0.05, 0.5 and 5 µM pentamidine (-60%, 
P<0.001; -80.13%, P<0.001; and -95%, P<0.001, respectively) 
compared with untreated cells (Fig. 1D and E).
Effect of pentamidine on p53, MMP‑2 and AQP‑4 protein 
expression levels. Compared with the untreated cells, incu-
bation of C6 cells with pentamidine induced a significant 
and concentration dependent upregulation of p53 protein 
expression (681±87.5%, P<0.05; 1244±94.3%, P<0.01; and 
2244±111%, P<0.001, respectively; Fig. 2A and B). In line 
with this, the expression of MMP-2 (42±2.3%, P<0.05; 
71±2.5%, P<0.01; and 95.8±3.3%, P<0.001, respectively) and 
AQP4 (38±2.5%, P<0.05; 69±2.6%, P<0.01; and 88±3.0%, 
P<0.001, respectively) were significantly lower in pentami-
dine-treated cells compared with untreated cells.
Effect of pentamidine on C6 cell migration in vitro. Malignant 
gliomas are characterized by aberrant proliferative activity, 
migration and invasion. The wound healing assay was used 
to evaluate the putative effect of pentamidine treatment on 
C6 cell migration. As indicated in Fig. 3A, while untreated 
C6 cells were able to invade and fully recolonize the 
scratched area within 48 h, the migration of cells treated with 
0.05, 0.5 and 5 µM pentamidine was significantly impaired 
in a concentration-dependent manner (88±4.2%, P<0.05; 
64±2%, P<0.01; and 42±3.1%, P<0.001, respectively), with 
the distance between the borders of the wound significantly 
different compared to that measured in the untreated cells. 
Furthermore, at a concentration of 5 µM, pentamidine caused 
an almost complete absence of migration (Fig. 3B).
Discussion
Despite the aggressive surgical and adjuvant treatments 
currently used for the management of malignant glioma, few 
advances have been made in determining the optimal thera-
peutic approach to this disease (27). However, the results of 
the present study demonstrate that pentamidine significantly 
decreases C6 rat glioma cell proliferation, exerting a pro-apop-
totic effect and, thus, highlighting pentamidine as a possible 
therapeutic agent in the treatment of malignant glioma.
Anti-apoptotic Bcl-2 protein, and pro-apoptotic BAX 
protein are two well-characterized signaling molecules that 
exhibit opposing functions and expression levels, with their 
ratio profoundly influencing the rate of cell apoptosis and 
survival (28). The activity of Bcl-2, a potent inhibitor of 
Figure 3. Pentamidine inhibits glioma cell migration in vitro. (A) Wound healing assay demonstrating the effect of pentamidine on cell migration in vitro. 
Hoechst staining of cell nuclei indicates that pentamidine inhibits the migration of C6 rat glioma cells in a concentration‑dependent manner (scale bar, 200 µm). 
(B) Quantification of cell migration (%). Results are expressed as the mean ± standard error of the mean of n=4 experiments performed in triplicate. *P<0.05; 
**P<0.01; and ***P<0.001 vs. ctrl cells. Ctrl, control.
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cell death, has been extensively described in the resistance 
to numerous anticancer chemotherapeutic agents, as well as 
in cancer development. By contrast, BAX protein is known 
to induce apoptosis in various cell lines (29). In concurrence 
with the antiproliferative activity of pentamidine described in 
a number of other cell types, including cultured human mela-
noma cells (16,17,30,31), the results of the present study indicate 
that pentamidine treatment dose-dependently increases the 
BAX/Bcl-2 ratio, demonstrating the pro-apoptotic role of this 
antiprotozoal agent in cultured glioma cells. The pro-apoptotic 
effect displayed by pentamidine appears to be directly asso-
ciated with the inhibition of the S100B-p53 protein-protein 
interaction, resulting in a marked restoration of wild-type 
p53 protein function. This effect is considered to be the pivotal 
mechanism of the anticancer effect of pentamidine (17,30,31). 
Among the various factors involved in the acquisition of inva-
sive capacities by tumor cells, MMP-2 and AQP4 have emerged 
as critical markers of glioma cell migration. MMP-2 belongs 
to a large family of extracellular matrix degrading enzymes, 
reported to be associated with tumor invasion (32), while 
AQP4 is a member of the water channel aquaporins (AQPs) 
that correlate with tumor progression and angiogenesis (33). 
At least 13 AQPs have been identified in mammals and are 
expressed by various cell types, including epithelium and 
endothelium cells (34); among these, AQP4 has a key role in 
glial cell migration (35). For example, it has been reported that 
AQP4 is significantly upregulated in glioblastoma compared 
with low grade gliomas and healthy brain tissue (35). Further-
more, AQP4 knockdown in rat and human cells has been 
associated with decreased cell migration and invasion, indi-
cating that AQP4 may be involved in glioma malignancy (35). 
In addition to previous studies describing the antiprolif-
erative effect of pentamidine, the current preliminary data 
demonstrated that pentamidine treatment caused a profound 
inhibition of AQP-4 and MMP-2 proteins when compared 
with untreated C6 cells, resulting in a concentration-dependent 
inhibition of cell migration rate in vitro. Although the results 
of the present study are limited by its in vitro approach, the 
inhibition of the S100B-p53 crosstalk induced by pentamidine 
may represent a promising pharmacological tool to increase 
the suppression of glioma cell malignancy. In particular, 
inhibition of the S100B-p53 interaction appeared to induced 
a significant pro‑apoptotic effect as well as a reduction in the 
migratory capability of C6 rat glioma cells. As previously 
stated, surgical resection of glioma is limited due to the 
high rate of local relapse (35), which may be dependent on 
MMP-2 and AQP4 expression. Thus, we hypothesize that since 
pentamidine inhibits the expression of these proteins, it may 
reduce the risk of local recurrences of glioma.
Agents that are able to induce apoptosis as well as inhibit 
migration may expand the spectrum of possible pharmaco-
logical treatment strategies for cancer, in particular malignant 
glioma. Thus, pentamidine and other S100B-p53 inhibitors 
are promising compounds for the treatment of this highly 
malignant form of cancer. A phase II trial (clinicaltrials.gov; 
no. NCT00729807) investigating the effect of pentamidine in 
relapsed or refractory melanoma is currently under evalua-
tion (17). From a translational perspective, pentamidine only 
exhibits minimal crossing of the blood brain barrier. Therefore, 
studies have been conducted that aimed to increase the passage 
of pentamidine into the CNS by modifying its structure prior 
to its introduction into clinical practice (36,37). However, it has 
been established that pentamidine is slowly delivered to the 
CNS via a complex process involving multiple transporters, 
such as P-glycoprotein and multidrug resistance-associated 
protein (MRP) transporters (37). In particular, the interaction 
of [3H] pentamidine with P‑glycoprotein and MRP has been 
proposed as a possible strategy to improve the delivery of pent-
amidine to the CNS (36). Therefore, pentamidine analogues 
that are able to block the S100B-p53 protein-protein interaction 
are promising compounds for restoring p53 expression levels 
in patients with malignant melanoma and other types of cancer 
that overexpress S100B protein (38).
In conclusion, although the present study is an in vitro 
preliminary report and requires confirmation in vivo, the 
results pave the way for the development of novel compounds 
that may potentially impact on the future treatment strategies 
of glial cell-originating tumors.
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